N	Concordance
1	etoposide/cyclophosphamide (CBDCA/VP-16/CTX) with autologous marrow or stem cel
2	ermine the in vivo effect of IL-1alpha, CTX and/or carboplatin, mice bearing 14-
3	llections, which begin 10-14 days after CTX induction.  Following 4 weeks of res
4	se reduction apparent for IL-1alpha and CTX when used in this combination. These
5	g treatment with high-dose L-PAM and BU/CTX with subsequent PBSC  rescue and IFN
6	y alternating chemotherapy combinations (CTX, VCR, doxorubicin; MTX, and cytarab
7	ng course of high-dose cyclophosphamide (CTX) followed by granulocyte colony-st
8	d pretransplant treatment may be either CTX on days -6 and -5 and  TBI on days -
9	C study comparing CI  IDA with standard CTX/TBI or CTX/BU encouraged.  Regimen B
10	trains led to tandem duplication of the CTX genetic element in the chromosome of